Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.16 - $11.84
Previous Close$6.59
Volume1.55M
Average Volume (3M)1.39M
Market Cap
$1.34B
Enterprise Value$462.87M
Total Cash (Recent Filing)$638.78M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 07, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding145,984,180
10 Day Avg. Volume1,321,567
30 Day Avg. Volume1,388,033
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue22.04K
Enterprise Value/Gross Profit51.43K
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$30.00Price Target Upside227.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsETNB reaffirmed their clinical data timing for lead asset pegozafermin in NASH and severe hypertriglyceridemia, with no surprises in their earnings update.
Regulatory PathwayPlans for accelerated and conditional approval in the U.S. and Europe for pegozafermin based on positive data from the ENLIGHTEN trials indicate potential future success.
Treatment EfficacyPegozafermin is well-positioned as a potentially best-in-class compound due to its competitive efficacy profile and differentiation on safety, tolerability, and dosing frequency.
Bears Say
Commercial ViabilityGreater clarity on pegozafermin’s clinical profile is needed to understand positioning within the rapidly expanding NASH landscape and the associated commercial opportunity.
Market CompetitionPivotal data from competitors in the sHTG treatment landscape could reset the clinical and commercial bar for physician adoption.
Regulatory ChallengesA second pivotal trial in SHTG will be required for approval, potentially delaying the BLA filing process.
89bio News
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $4.16 and its highest was $11.84 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $1.34B.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Aug 07, 2025 which is in 3 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on May 01, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.554 by $0.064.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.5.
How many shares outstanding does 89bio have?
89bio has 145,984,180 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.554. Following the earnings report the stock price went up 7.38%.
Which hedge fund is a major shareholder of 89bio?
Currently, no hedge funds are holding shares in ETNB
89bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (227.51% Upside)
$30.00 (227.51% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 6.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.06%
12-Months-Change
Fundamentals
Return on Equity
-69.30%
Trailing 12-Months
Asset Growth
18.66%
Trailing 12-Months
Company Description
89bio
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Stock 12 Month Forecast
Average Price Target
$30.00
▲(227.51%Upside)
Technical Analysis
Spyre Therapeutics
―
Arcus Biosciences
―
Vir Biotechnology
―
Enliven Therapeutics
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
15.01% Insiders
14.64% Mutual Funds
1.65% Other Institutional Investors
56.69% Public Companies and
Individual Investors